Cargando…

Therapeutic effect of fenofibrate for non-alcoholic steatohepatitis in mouse models is dependent on regime design

Background: Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver diseases. In most cases, NAFLD progresses from benign steatosis to steatohepatitis (NASH), and then to cirrhosis. No treatment is currently approved for NAFLD/NASH in the clinic. Fenofibrate (FENO) has been c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xinxue, Luo, Jia, Lu, Zhuoheng, Fang, Shenzhe, Sun, Mengxia, Luo, Wenjing, Shen, Jianwei, Liu, Aiming, Ye, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213340/ https://www.ncbi.nlm.nih.gov/pubmed/37251331 http://dx.doi.org/10.3389/fphar.2023.1190458

Ejemplares similares

Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
por: Takai, Shinji, et al.
Publicado: (2018)

Fructose and Non-Alcoholic Steatohepatitis
por: Roeb, Elke, et al.
Publicado: (2021)

The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment
por: Yu, Lili, et al.
Publicado: (2022)

Current, emerging, and potential therapies for non-alcoholic steatohepatitis
por: Yang, Zhen, et al.
Publicado: (2023)

Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis
por: Luo, Wei, et al.
Publicado: (2023)

Therapeutic response analysis for patients with adenosquamous carcinoma of the gallbladder: data analysis based on the Surveillance, Epidemiology, and End Results (SEER) database
por: Fang, Shenzhe, et al.
Publicado: (2023)

Psoralea corylifolia L. Attenuates Nonalcoholic Steatohepatitis in Juvenile Mouse
por: Zhou, Lishan, et al.
Publicado: (2017)

A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis
por: Kawaguchi-Suzuki, Marina, et al.
Publicado: (2018)

Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
por: Peng, Cheng, et al.
Publicado: (2020)

Artemether Ameliorates Non-Alcoholic Steatohepatitis by Repressing Lipogenesis, Inflammation, and Fibrosis in Mice
por: Xu, Jia, et al.
Publicado: (2022)

Geniposide and Chlorogenic Acid Combination Ameliorates Non-alcoholic Steatohepatitis Involving the Protection on the Gut Barrier Function in Mouse Induced by High-Fat Diet
por: Peng, Jing-hua, et al.
Publicado: (2018)

Geniposide plus chlorogenic acid reverses non-alcoholic steatohepatitis via regulation of gut microbiota and bile acid signaling in a mouse model in vivo
por: Li, Hongshan, et al.
Publicado: (2023)

Fenofibrate Decreases Hepatic P-Glycoprotein in a Rat Model of Hereditary Hypertriglyceridemia
por: Poruba, Martin, et al.
Publicado: (2019)

Role of Alternative Lipid Excipients in the Design of Self-Nanoemulsifying Formulations for Fenofibrate: Characterization, in vitro Dispersion, Digestion and ex vivo Gut Permeation Studies
por: Alshamsan, Aws, et al.
Publicado: (2018)

Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish
por: Ashikawa, Yoshifumi, et al.
Publicado: (2016)

Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
por: Kuo, Joseph, et al.
Publicado: (2019)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids
por: Jian, Jie, et al.
Publicado: (2022)

Research landscape and frontiers of non-alcoholic steatohepatitis-associated hepatocellular carcinoma: a bibliometric and visual analysis
por: Gao, Bowen, et al.
Publicado: (2023)

The Inhibitory T Cell Receptors PD1 and 2B4 Are Differentially Regulated on CD4 and CD8 T Cells in a Mouse Model of Non-alcoholic Steatohepatitis
por: Hansel, Cordula, et al.
Publicado: (2019)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study
por: Das, Mithun, et al.
Publicado: (2015)

Fenofibrate suppresses corneal neovascularization by regulating lipid metabolism through PPARα signaling pathway
por: Zhou, Tong, et al.
Publicado: (2022)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXRα Signaling
por: Chen, Yu-jun, et al.
Publicado: (2021)

Evaluation of the efficacy of mitochondrial fission inhibitor (Mdivi-1) using non-alcoholic steatohepatitis (NASH) liver organoids
por: Elbadawy, Mohamed, et al.
Publicado: (2023)

The clinical characteristics of pancreatic colloid carcinoma and the development and validation of its cancer-specific survival prediction nomogram
por: Wang, Xinxue, et al.
Publicado: (2023)

Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Wu, Jingyi, et al.
Publicado: (2023)

Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice
por: Zhang, Dan, et al.
Publicado: (2022)

The Hyperlipidaemic Drug Fenofibrate Significantly Reduces Infection by SARS-CoV-2 in Cell Culture Models
por: Davies, Scott P., et al.
Publicado: (2021)

A Mendelian randomization study for drug repurposing reveals bezafibrate and fenofibric acid as potential osteoporosis treatments
por: Li, Xiao-Hua, et al.
Publicado: (2023)

Erratum: Bicyclol attenuates high fat diet-induced non-alcoholic fatty liver disease/non-alcoholic steatohepatitis through modulating multiple pathways in mice
por: Frontiers Production Office,
Publicado: (2023)

Medicinal Formula Huazhi-Rougan Attenuates Non-Alcoholic Steatohepatitis Through Enhancing Fecal Bile Acid Excretion in Mice
por: Li, Chunlin, et al.
Publicado: (2022)

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice
por: Li, Shengjie, et al.
Publicado: (2022)

Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate
por: Rajamoorthi, Ananthi, et al.
Publicado: (2017)

Periplaneta americana extract alleviates steatohepatitis in a mouse model by modulating HMGB1-mediated inflammatory response
por: Xiao, Yang, et al.
Publicado: (2022)

Fenofibrate Inhibits Subretinal Fibrosis Through Suppressing TGF‐β—Smad2/3 signaling and Wnt signaling in Neovascular Age‐Related Macular Degeneration
por: Chen, Qian, et al.
Publicado: (2020)

Gut-Derived Serotonin Contributes to the Progression of Non-Alcoholic Steatohepatitis via the Liver HTR2A/PPARγ2 Pathway
por: Wang, Lulu, et al.
Publicado: (2020)

Exploring the molecular mechanism of Gan Shuang granules for the treatment of non-alcoholic steatohepatitis using network pharmacology, molecular docking, and experimental verification
por: Zhi, Guoguo, et al.
Publicado: (2023)

Anti-Autophagy Mechanism of Zhi Gan Prescription Based on Network Pharmacology in Nonalcoholic Steatohepatitis Rats
por: Qin, Chufeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_smc9sqmfndih884gre5am2pu1u